KR20080020738A - 항염활성 및 골대사 관련인자 억제활성을 나타내는까마귀쪽나무 추출물 - Google Patents
항염활성 및 골대사 관련인자 억제활성을 나타내는까마귀쪽나무 추출물 Download PDFInfo
- Publication number
- KR20080020738A KR20080020738A KR1020060083944A KR20060083944A KR20080020738A KR 20080020738 A KR20080020738 A KR 20080020738A KR 1020060083944 A KR1020060083944 A KR 1020060083944A KR 20060083944 A KR20060083944 A KR 20060083944A KR 20080020738 A KR20080020738 A KR 20080020738A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- activity
- juss
- litsea japonica
- bone
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 92
- 230000003110 anti-inflammatory effect Effects 0.000 title claims description 13
- 230000000694 effects Effects 0.000 title abstract description 23
- 241001149157 Litsea japonica Species 0.000 title abstract description 12
- 230000005764 inhibitory process Effects 0.000 title description 23
- 230000004097 bone metabolism Effects 0.000 title description 9
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 45
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 32
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 28
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims abstract description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 230000002829 reductive effect Effects 0.000 claims abstract description 15
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 14
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000469 ethanolic extract Substances 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 8
- 239000006228 supernatant Substances 0.000 claims abstract description 7
- 239000012141 concentrate Substances 0.000 claims abstract description 6
- 239000012153 distilled water Substances 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000001035 drying Methods 0.000 claims abstract description 4
- 235000013373 food additive Nutrition 0.000 claims abstract description 3
- 239000002778 food additive Substances 0.000 claims abstract description 3
- 239000000725 suspension Substances 0.000 claims abstract description 3
- 230000002503 metabolic effect Effects 0.000 claims abstract 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 101
- 238000004519 manufacturing process Methods 0.000 claims description 31
- 230000003078 antioxidant effect Effects 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 19
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 claims description 11
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 230000001766 physiological effect Effects 0.000 claims description 7
- 208000030159 metabolic disease Diseases 0.000 claims description 5
- 241000723346 Cinnamomum camphora Species 0.000 claims description 4
- 235000012778 Empetrum nigrum Nutrition 0.000 claims description 4
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 3
- 241001415939 Corvus Species 0.000 claims description 3
- 229960000846 camphor Drugs 0.000 claims description 3
- 229930008380 camphor Natural products 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- XSKZXGDFSCCXQX-UHFFFAOYSA-N thiencarbazone-methyl Chemical compound COC(=O)C1=CSC(C)=C1S(=O)(=O)NC(=O)N1C(=O)N(C)C(OC)=N1 XSKZXGDFSCCXQX-UHFFFAOYSA-N 0.000 claims description 3
- 241001081179 Litsea Species 0.000 claims description 2
- 235000012854 Litsea cubeba Nutrition 0.000 claims description 2
- 244000184734 Pyrus japonica Species 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- 238000002604 ultrasonography Methods 0.000 claims description 2
- 241000194010 Empetrum Species 0.000 claims 3
- 239000002516 radical scavenger Substances 0.000 claims 2
- 239000003064 xanthine oxidase inhibitor Substances 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 abstract description 23
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 23
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract description 19
- 230000004054 inflammatory process Effects 0.000 abstract description 9
- 206010061218 Inflammation Diseases 0.000 abstract description 8
- 229960002986 dinoprostone Drugs 0.000 abstract description 8
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract description 8
- 208000001132 Osteoporosis Diseases 0.000 abstract description 4
- 229940100601 interleukin-6 Drugs 0.000 abstract description 2
- 208000002865 osteopetrosis Diseases 0.000 abstract description 2
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 abstract 2
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 abstract 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 abstract 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 abstract 1
- 238000007598 dipping method Methods 0.000 abstract 1
- 238000010298 pulverizing process Methods 0.000 abstract 1
- 238000000527 sonication Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 36
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 23
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 23
- 230000002292 Radical scavenging effect Effects 0.000 description 23
- 230000015572 biosynthetic process Effects 0.000 description 22
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 19
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 19
- 239000002037 dichloromethane fraction Substances 0.000 description 19
- 108010093894 Xanthine oxidase Proteins 0.000 description 18
- 239000002038 ethyl acetate fraction Substances 0.000 description 18
- 102100033220 Xanthine oxidase Human genes 0.000 description 17
- 239000002044 hexane fraction Substances 0.000 description 17
- 210000000963 osteoblast Anatomy 0.000 description 14
- 231100000135 cytotoxicity Toxicity 0.000 description 11
- 230000003013 cytotoxicity Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000017306 interleukin-6 production Effects 0.000 description 10
- 210000002997 osteoclast Anatomy 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000002000 scavenging effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 6
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 6
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 6
- 230000028709 inflammatory response Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 150000002978 peroxides Chemical class 0.000 description 6
- 230000009257 reactivity Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229940116269 uric acid Drugs 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 5
- 241000557626 Corvus corax Species 0.000 description 5
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 5
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 5
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 5
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 229940011871 estrogen Drugs 0.000 description 5
- 239000000262 estrogen Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 4
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 4
- 239000006180 TBST buffer Substances 0.000 description 4
- 239000002034 butanolic fraction Substances 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229940075420 xanthine Drugs 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 3
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 3
- 229960003459 allopurinol Drugs 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 241001070941 Castanea Species 0.000 description 2
- 235000014036 Castanea Nutrition 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitrogen oxide(NO) Natural products O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 208000027868 Paget disease Diseases 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 2
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 241001233957 eudicotyledons Species 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- -1 lactone compound Chemical class 0.000 description 2
- 208000027202 mammary Paget disease Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000007348 radical reaction Methods 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241001656830 Arctous rubra Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 244000169938 Empetrum nigrum Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 101000998969 Homo sapiens Inositol-3-phosphate synthase 1 Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical group OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102100036881 Inositol-3-phosphate synthase 1 Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000012163 TRI reagent Substances 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 102000005773 Xanthine dehydrogenase Human genes 0.000 description 1
- 108010091383 Xanthine dehydrogenase Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 235000019730 animal feed additive Nutrition 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 108010009896 bone resorption factor Proteins 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000000453 juniperus communis l. leaf oil Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
처리 | IC50(㎍/㎖)a) | ||
DPPH 라디칼 소거활성 | 크산틴 산화효소 억제활성 | 과산화물 라디칼 소거활성 | |
에탄올추출물 | 52.02 ± 1.72 | > 1000 | > 1000 |
헥산분획물 | 669.29 ± 2.83 | > 1000 | > 1000 |
디클로로메탄 분획물 | 56.54 ± 1.75 | > 1000 | 243.51 ± 2.39 |
에틸아세테이트 분획물 | 13.61 ± 1.13 | 453.86 ± 2.66 | 25.19 ± 1.40 |
부탄올분획물 | 31.25 ± 1.49 | > 1000 | > 1000 |
물 분획물 | 114.24 ± 2.06 | > 1000 | > 1000 |
BHAb ) | 22.70 ± 0.61 | NAc ) | NAc ) |
아스코르빈산 | 3.90 ± 3.22 | - | - |
트롤록스 | 8.62 ± 2.20 | 288.60 ± 4.4 | 189.9 ± 2.03 |
알로푸리놀 | NAc ) | 3.12 ± 0.17 | 22.65 ± 0.35 |
유전자 | 프라이머 서열 | 서열번호 | 단편크기 | ||
RAW 264.7 | COX-2 | F | 5'-CACTACATCCTGACCCACTT-3' | 1 | 696 bp |
R | 5'-ATGCTCCTGCTTGAGTATGT-3' | 2 | |||
iNOS | F | 5'-CCCTTCCGAAGTTTCTGGCAGCAGC-3' | 3 | 496 bp | |
R | 5'-GGCTGTCAGAGCCTCGTGGCTTTGG-3' | 4 | |||
β-Actin | F | 5'-GTGGGCCGCCCTAGGCACCAG-3' | 5 | 603 bp | |
R | 5'-GGAGGAAGAGGATGCGGCAGT-3' | 6 | |||
MG-63 | IL-6 | F | 5'-AATTCGGTACATCCTCGACG-3' | 7 | 421 bp |
R | 5'-GCGCAGAATGAGATGAGTTG-3' | 8 | |||
β-Actin | F | 5'-ATGGGTCAGAAGGATTCCTATG-3' | 9 | 588 bp | |
R | 5'-CAGCTCGTAGCTCTTCTCCA-3' | 10 |
Claims (5)
- 녹나무과 추출물에 있어서,까마귀쪽나무(Litsea japonica juss)의 잎, 줄기, 열매 중 선택된 1종 이상을 준비하고, 음건한 다음, 마쇄기로 분쇄한 분말을 80 % 에탄올에 침적하고, 초음파를 이용하여 1시간씩 3회 추출하여 에탄올추출물을 제조하고, 그 추출물의 상층액을 회수하여 감압 농축하고, 농축물을 증류수에 현탁시킨 후, 현탁액을 헥산, 디클로로메탄, 에틸아세테이트, 부탄올로 순차적으로 추출하여 제조된 까마귀쪽나무 추출물 및 분획물로서,항산화활성, 항염활성, 골대사성 관련 인자 억제활성 중 1 종 이상의 생리활성을 갖는 것이 특징인,생리활성을 나타내는 까마귀쪽나무 추출물.
- 제1항의 까마귀쪽나무 추출물을 유효성분으로 포함하는,DPPH 라디칼 소거제, 크산틴 산화효소(Xanthine Oxidase) 저해제, 과산화물(Superoxide) 라디칼 소거제, 산화질소(Nitric Oxide) 생성 저해제 중 선택된 1종 이상의 항산화용 조성물.
- 제1항의 까마귀쪽나무 추출물을 유효성분으로 포함하는,염증성 질환의 예방 및 치료용 조성물.
- 제1항의 까마귀쪽나무 추출물을 유효성분으로 포함하는,골대사성 질환의 예방 및 치료용 조성물.
- 제1항에 있어서,식품첨가제 또는 음료조성물에 첨가되는 것이 특징인,생리활성을 나타내는 까마귀쪽나무 추출물.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060083944A KR100812095B1 (ko) | 2006-09-01 | 2006-09-01 | 항염활성 및 골대사 관련인자 억제활성을 나타내는까마귀쪽나무 추출물 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060083944A KR100812095B1 (ko) | 2006-09-01 | 2006-09-01 | 항염활성 및 골대사 관련인자 억제활성을 나타내는까마귀쪽나무 추출물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080020738A true KR20080020738A (ko) | 2008-03-06 |
KR100812095B1 KR100812095B1 (ko) | 2008-03-12 |
Family
ID=39395513
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060083944A KR100812095B1 (ko) | 2006-09-01 | 2006-09-01 | 항염활성 및 골대사 관련인자 억제활성을 나타내는까마귀쪽나무 추출물 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100812095B1 (ko) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012021035A2 (ko) * | 2010-08-13 | 2012-02-16 | 한국한의학연구원 | 까마쪽나무 추출물 또는 이의 분획물을 유효성분으로 함유하는 당뇨합병증 예방 및 치료용 조성물 |
WO2014182004A1 (ko) * | 2013-05-06 | 2014-11-13 | (주) 휴럼 | 까마귀쪽나무의 오일을 유효성분으로 함유하는 염증성 질환 예방 및 치료용 조성물과 이의 제조방법 |
WO2014208888A1 (ko) * | 2013-06-24 | 2014-12-31 | (주) 휴럼 | 까마귀쪽나무 열매로부터 추출되는 정유성분을 포함하는 위장질환 예방 및 치료용 조성물 |
KR20150073711A (ko) * | 2013-12-23 | 2015-07-01 | 재단법인 제주테크노파크 | 까마귀쪽나무 미성숙과 추출물 또는 이로부터 분리된 화합물을 이용한 항염증용 조성물 |
KR20160076112A (ko) * | 2014-12-22 | 2016-06-30 | 재단법인 제주테크노파크 | 까마귀쪽나무 추출물과 이로부터 분리된 Litseakolide D2를 이용한 항염증용 조성물 |
KR101700348B1 (ko) * | 2016-01-22 | 2017-01-26 | 재단법인 제주테크노파크 | 까마귀쪽나무 잎 또는 그 열매 추출물을 이용한 관절염 개선용 조성물 |
-
2006
- 2006-09-01 KR KR1020060083944A patent/KR100812095B1/ko active IP Right Grant
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012021035A2 (ko) * | 2010-08-13 | 2012-02-16 | 한국한의학연구원 | 까마쪽나무 추출물 또는 이의 분획물을 유효성분으로 함유하는 당뇨합병증 예방 및 치료용 조성물 |
WO2012021035A3 (ko) * | 2010-08-13 | 2012-05-10 | 한국한의학연구원 | 까마쪽나무 추출물 또는 이의 분획물을 유효성분으로 함유하는 당뇨합병증 예방 및 치료용 조성물 |
KR101243243B1 (ko) * | 2010-08-13 | 2013-03-13 | 한국 한의학 연구원 | 까마귀쪽나무 추출물 또는 이의 분획물을 유효성분으로 함유하는 당뇨합병증 예방 및 치료용 조성물 |
WO2014182004A1 (ko) * | 2013-05-06 | 2014-11-13 | (주) 휴럼 | 까마귀쪽나무의 오일을 유효성분으로 함유하는 염증성 질환 예방 및 치료용 조성물과 이의 제조방법 |
CN105209052A (zh) * | 2013-05-06 | 2015-12-30 | 合仑有限公司 | 包含山苍粳的油作为有效成分的炎症性疾病预防及治疗用组合物及其制备方法 |
US20190151391A1 (en) * | 2013-05-06 | 2019-05-23 | Hurum Co., Ltd. | Composition for preventing and treating inflammatory disease, containing oil of litsea japonica as active ingredient, and method for preparing same |
WO2014208888A1 (ko) * | 2013-06-24 | 2014-12-31 | (주) 휴럼 | 까마귀쪽나무 열매로부터 추출되는 정유성분을 포함하는 위장질환 예방 및 치료용 조성물 |
KR20150073711A (ko) * | 2013-12-23 | 2015-07-01 | 재단법인 제주테크노파크 | 까마귀쪽나무 미성숙과 추출물 또는 이로부터 분리된 화합물을 이용한 항염증용 조성물 |
KR20160076112A (ko) * | 2014-12-22 | 2016-06-30 | 재단법인 제주테크노파크 | 까마귀쪽나무 추출물과 이로부터 분리된 Litseakolide D2를 이용한 항염증용 조성물 |
KR101700348B1 (ko) * | 2016-01-22 | 2017-01-26 | 재단법인 제주테크노파크 | 까마귀쪽나무 잎 또는 그 열매 추출물을 이용한 관절염 개선용 조성물 |
Also Published As
Publication number | Publication date |
---|---|
KR100812095B1 (ko) | 2008-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lin et al. | Antioxidant activity of Cinnamomum cassia | |
KR100812095B1 (ko) | 항염활성 및 골대사 관련인자 억제활성을 나타내는까마귀쪽나무 추출물 | |
Kim et al. | Extracts of Actinidia arguta stems inhibited LPS-induced inflammatory responses through nuclear factor–κB pathway in Raw 264.7 cells | |
Jo et al. | Radical scavenging activities of tannin extracted from amaranth (Amaranthus caudatus L.) | |
JP2014511171A (ja) | 機能性食品製剤及びその使用 | |
Shettar et al. | Evaluation of in vitro antioxidant and anti-inflammatory activities of Ximenia americana extracts | |
KR101161479B1 (ko) | 왕겨초액을 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학 조성물 | |
Lee et al. | Medicinal effects of bromelain (Ananas comosus) targeting oral environment as an anti-oxidant and anti-inflammatory agent | |
Lee et al. | Anti-inflammatory effect of Malus domestica cv. Green ball apple peel extract on Raw 264.7 macrophages | |
Joo et al. | Glycoprotein isolated from Cudrania tricuspidata Bureau inhibits iNO and COX-2 expression through modulation of NF-κB in LPS-stimulated RAW 264.7 cells | |
KR20090112955A (ko) | 항염증 활성을 갖는 몰로키아 추출물을 함유하는 식품 | |
Salazar et al. | Role of Dietary Polyphenols in Adipose Tissue Browning: A Narrative Review | |
KR100835214B1 (ko) | 항산화활성 및 골대사 관련인자 억제활성을 나타내는청동풍뎅이 추출물 | |
KR100829083B1 (ko) | 생리활성을 갖는 애기달맞이 추출물 | |
KR100768085B1 (ko) | 생리활성을 가지는 비쑥추출물 | |
WO2014171333A1 (ja) | ミトコンドリア活性化剤 | |
KR20080028029A (ko) | 오동나무 잎 추출물을 포함하는 화장료 조성물 | |
KR20070005049A (ko) | 미백활성을 갖는 제주조릿대 잎 추출물 | |
Ezin et al. | Azadirachta indica: Its biological, pharmacological, antidiabetic potential, and omics applications | |
Park et al. | Inhibitory effects of eutigosides isolated from Eurya emarginata on the inflammatory mediators in RAW264. 7 cells | |
Djarmouni et al. | Anti-inflammatory and xanthine oxidase inhibition activities of Santolina chamaecyparissus extracts | |
JP5085198B2 (ja) | 抗酸化剤 | |
KR20110138732A (ko) | 참죽나무 추출물을 함유하는 항염증 조성물 | |
KR20090112954A (ko) | 항동맥경화 활성을 갖는 몰로키아 추출물을 함유하는 식품 | |
Gandhi et al. | In-vitro assay of anti-proliferative potential of Amaranthus cruentus aqueous extract on human peripheral blood lymphocytes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
G170 | Re-publication after modification of scope of protection [patent] | ||
FPAY | Annual fee payment |
Payment date: 20130305 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140227 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20160712 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20170302 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20180226 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20190304 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20200226 Year of fee payment: 13 |